Customer Portal

“To enable the widespread adoption needed to make an impact on this problem, susceptibility testing systems need to be accurate, provide same-shift results, have a broad antimicrobial menu, and be easy to use,”

- Dr. Tibbetts, Assoc. Dir. of Clinical Microbiology

ANTIMICROBIAL RESISTANCE

What is antimicrobial resistance (AMR)?

AMR is ability of bacteria to resist the effects of an antibiotic and continue to multiply causing more patient harm.

Antibiotic resistance is one of the biggest public health challenges of our time.1

Each year in the US, at least 2.8M people get an antibiotic-resistant infection, and more than 35,000 people die.1

Globally, about 700,000 deaths may be caused each year by AMR.2

Estimated annual national cost to treat infections caused by multidrug-resistant germs more than $4.6 billion.3

Bacteria in the Carbapenem-resistant Enterobacteriaceae (CRE) family are resistant to nearly all antibiotics, leaving only toxic or less effective treatment options.4

 

Specific Diagnostics' Impact on AMR

AMR is accelerated by misuse and overuse of antibiotics.

Hospitalized patients with suspected blood infections are given broad spectrum antibiotics as the care team waits for their infection identification and antimicrobial susceptibility results. Obtaining these results can take over 2 days days, which can lead to AMR due to patients being on unneeded antibiotics that aren’t optimal for their specific infection.

The SPECIFIC REVEAL Rapid AST System produces AST results within an average of 5.5 hours directly from blood culture.5  This allows the patient’s care team to switch them to the optimal antibiotic therapy up to 2 days sooner than with traditional AST methods. This rapid de-escalation of antibiotic therapy can help prevent AMR from occurring due to overuse of unneeded antibiotics.

1 https://www.cdc.gov/drugresistance/index.html
2 https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf
3 https://www.cdc.gov/drugresistance/biggest-threats.html
4 https://www.cdc.gov/hai/organisms/cre/cre-patients.html
5 Rottman M et al. ECCMID 2022. Clinical evaluation of the SPECIFIC REVEAL™ Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England.
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback
Feedback